Targeting the tumor microenvironment with SRC kinase inhibition.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20103657.
- Also identified by DOI 10.1158/1078-0432.CCR-09-3081.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although most cancer therapies are directed against tumor cells, an emerging area of cancer therapeutics focuses on targeting cells of the tumor microenvironment. Inhibiting the Src family kinase with dasatinib decreases tumor growth through inhibiting growth of tumor-associated endothelial and myeloid cells.
Medical subject headings
- Fusion Proteins, bcr-abl
- Neoplasms
- Protein Kinase Inhibitors
- Pyrimidines
- Stromal Cells
- Thiazoles
- src-Family Kinases